Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DiaSorin Strikes Dx Partnership With MeMed To Address Antibiotic Overuse

Executive Summary

First licensing agreement for MeMed adds its immune system-based protein signature test to DiaSorin’s LIAISON test menu.

You may also be interested in...



MeMed Ready To Partner On IVD Technology That Can Cut Antibiotic Overuse

MeMed has received CE Marking for its diagnostic test MeMed BV and point-of-need platform MeMed Key, which uses the human immune system to distinguish between bacterial and viral infections to prevent antibiotic overuse.

Start-Up Spotlight: MeMed, Making Infectious Disease Dx Clearer With Immune Responsive Signatures

Israeli company MeMed has developed a proprietary diagnostic platform which uses proprietary immune system biomarkers to rapidly distinguish between viral and bacterial infections. The firm already has a CE -marked lab-based product, ImmunoXpert, which has been validated in three studies, the last of that trilogy having just published results confirming the test's ability to accurately distinguish between bacterial and viral infections.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT142708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel